UBS Group
COGT icon

UBS Group’s Cogent Biosciences COGT Stock Holding History

UBS Group’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.4M Buy
1,122,245
+830,759
+285% +$29.1M 0.01% 1888
2026
Q1 		$11.2M Buy
291,486
+27,439
+10% +$1.01M ﹤0.01% 3205
2025
Q4 		$9.38M Sell
264,047
-1,589,625
-86% -$44.7M ﹤0.01% 3353
2025
Q3 		$26.6M Sell
1,853,672
-1,664,999
-47% -$19.7M ﹤0.01% 2254
2025
Q2 		$25.3M Buy
3,518,671
+414,541
+13% +$2.3M ﹤0.01% 2133
2025
Q1 		$18.6M Buy
3,104,130
+2,890,196
+1,351% +$22.7M ﹤0.01% 2402
2024
Q4 		$1.67M Buy
213,934
+98,439
+85% +$981K ﹤0.01% 4904
2024
Q3 		$1.25M Sell
115,495
-11,044
-9% -$108K ﹤0.01% 4447
2024
Q2 		$1.07M Sell
126,539
-304,466
-71% -$2.31M ﹤0.01% 4363
2024
Q1 		$2.9M Buy
431,005
+203,598
+90% +$1.26M ﹤0.01% 3557
2023
Q4 		$1.34M Buy
227,407
+148,333
+188% +$1.14M ﹤0.01% 4230
2023
Q3 		$771K Sell
79,074
-3,401
-4% -$40.3K ﹤0.01% 4312
2023
Q2 		$977K Sell
82,475
-10,475
-11% -$120K ﹤0.01% 4276
2023
Q1 		$1M Sell
92,950
-124,134
-57% -$1.59M ﹤0.01% 4096
2022
Q4 		$2.51M Buy
217,084
+184,452
+565% +$2.29M ﹤0.01% 3165
2022
Q3 		$487K Buy
32,632
+32,083
+5,844% +$440K ﹤0.01% 4364
2022
Q2 		$5K Buy
549
+130
+31% +$887 ﹤0.01% 8852
2022
Q1 		$3K Buy
+419
New +$2.92K ﹤0.01% 9431
2021
Q4 		– Sell
-258
Closed -$2K – 10303
2021
Q3 		$2K Buy
+258
New +$1.98K ﹤0.01% 8936
2020
Q4 		– Sell
-85
Closed -$1K – 8426
2020
Q3 		$1K Buy
+85
New +$886 ﹤0.01% 7766
2020
Q2 		– Sell
-2,119
Closed -$4K – 7978
2020
Q1 		$4K Buy
+2,119
New +$5.89K ﹤0.01% 7377
2018
Q4 		– Sell
-2,109
Closed -$87K – 8058
2018
Q3 		$87K Buy
2,109
+1,279
+154% +$72.1K ﹤0.01% 5701
2018
Q2 		$48K Buy
+830
New +$39.9K ﹤0.01% 5985

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS Group's COGT Position: Q2 2026 in Review

UBS Group increased its Cogent Biosciences (COGT) stake by 285% in Q2 2026, buying an estimated $29.1M and bringing the position to 1,122,245 shares worth $43.4M. The position accounts for 0.01% of the portfolio, ranked #1888.

UBS Group first reported a position in COGT in Q2 2018 and has held it in 23 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • UBS Group held 1,122,245 shares of Cogent Biosciences worth $43.4M as of Q2 2026.
  • UBS Group bought 830,759 Cogent Biosciences shares in Q2 2026, an estimated $29.1M.
  • Cogent Biosciences made up 0.01% of UBS Group's portfolio in Q2 2026, its #1888 holding.
  • UBS Group first reported a position in Cogent Biosciences in Q2 2018 and has held it in 23 quarters since.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.